Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy.
暂无分享,去创建一个
A. Jauch | F. Wenz | W. Zeller | S. Fruehauf | M. Veldwijk | S. Laufs | S. Berlinghoff | W. Jens Zeller | Hans-Peter Maser
[1] F. Wenz,et al. Suicide gene therapy of sarcoma cell lines using recombinant adeno-associated virus 2 vectors , 2004, Cancer Gene Therapy.
[2] H. Mizukami,et al. Suicide gene therapy using AAV-HSVtk/ganciclovir in combination with irradiation results in regression of human head and neck cancer xenografts in nude mice , 2003, Gene Therapy.
[3] N. Muzyczka,et al. Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. , 2002, Anticancer research.
[4] F. Wenz,et al. Development and optimization of a real-time quantitative PCR-based method for the titration of AAV-2 vector stocks. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[5] Y. Ikeda,et al. Gene transduction efficiency in cells of different species by HIV and EIAV vectors , 2002, Gene Therapy.
[6] P. Lønning,et al. Adeno-associated viral vectors penetrate human solid tumor tissue in vivo more effectively than adenoviral vectors. , 2002, Human gene therapy.
[7] R. Gibson,et al. A phase I study of aerosolized administration of tgAAVCF to cystic fibrosis subjects with mild lung disease. , 2001, Human gene therapy.
[8] H. Yeh,et al. Intratumoral adenovirus-mediated suicide gene transfer for hepatic metastases from colorectal adenocarcinoma: results of a phase I clinical trial. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] P. Beard,et al. Virus-mediated killing of cells that lack p53 activity , 2001, Nature.
[10] I. Tohnai,et al. Suicide gene therapy for human oral squamous cell carcinoma cell lines with adeno-associated virus vector. , 2001, Oral oncology.
[11] B. Byrne,et al. CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. , 2001, Human gene therapy.
[12] H. Mizukami,et al. γ-Rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells , 2001, Cancer Gene Therapy.
[13] James M. Wilson,et al. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. , 2001, Human gene therapy.
[14] N. Rainov,et al. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: Applications for prodrug-activating gene therapy , 2000, Cancer Gene Therapy.
[15] B. Schiedlmeier,et al. Differential expression of a recombinant adeno-associated virus 2 vector in human CD34+ cells and breast cancer cells , 2000, Cancer Gene Therapy.
[16] Alan McClelland,et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector , 2000, Nature Genetics.
[17] B. Kleinschmidt-DeMasters,et al. Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms , 2000, Cancer Gene Therapy.
[18] J. Kleinschmidt,et al. Superior gene transfer into solid tumour cells than into human mobilised peripheral blood progenitor cells using helpervirus-free adeno-associated viral vector stocks. , 1999, European journal of cancer.
[19] T. Flotte,et al. Safety and Biological Efficacy of an Adeno‐Associated Virus Vector–Cystic Fibrosis Transmembrane Regulator (AAV‐CFTR) in the Cystic Fibrosis Maxillary Sinus , 1999, The Laryngoscope.
[20] D. Grimm,et al. Novel tools for production and purification of recombinant adenoassociated virus vectors. , 1998, Human gene therapy.
[21] R. Ramesh,et al. Clinical Protocol The Treatment of Malignant Mesothelioma with a Gene Modified Cancer Cell Line: A Phase I Study , 1998 .
[22] R. Ramesh,et al. The treatment of malignant mesothelioma with a gene modified cancer cell line: a phase I study. , 1998, Human gene therapy.
[23] James M. Wilson,et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. , 1998, Human gene therapy.
[24] P. Ye,et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. , 1998, American journal of respiratory cell and molecular biology.
[25] James M. Wilson,et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. , 1998, Human gene therapy.
[26] A. Salvetti,et al. Factors influencing recombinant adeno-associated virus production. , 1998, Human gene therapy.
[27] S. Ponnazhagan,et al. Adeno-Associated Virus Type 2-Mediated Gene Transfer: Correlation of Tyrosine Phosphorylation of the Cellular Single-Stranded D Sequence-Binding Protein with Transgene Expression in Human Cells In Vitro and Murine Tissues In Vivo , 1998, Journal of Virology.
[28] T. Flotte,et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. , 1996, Gene therapy.
[29] K. Tamayose,et al. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. , 1996, Human gene therapy.
[30] G. Fishman,et al. Gap junctions play a role in the 'bystander effect' of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. , 1996, Gene therapy.
[31] J. Peto,et al. Continuing increase in mesothelioma mortality in Britain , 1995, The Lancet.
[32] R. Warnick,et al. In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. , 1993, Human gene therapy.
[33] S. Freeman,et al. The "bystander effect": tumor regression when a fraction of the tumor mass is genetically modified. , 1993, Cancer research.
[34] A. Bogdén,et al. Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model. , 1987, Cancer research.
[35] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[36] E. Huang,et al. Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyl]-guanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1. , 1983, Proceedings of the National Academy of Sciences of the United States of America.